Click Here to View as a PDF
Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots | CDC Online Newsroom | CDC
The Sjögren’s Foundation COVID Vaccination Committee concurs with the August 18 announcement by U.S. government health officials recommending all Americans, including all Sjögren’s patients, obtain a booster COVID-19 immunization 8 months following the 2nd mRNA COVID-19 vaccination. For those who received a 3rd dose vaccination, new guidance will likely be announced, so watch for news of this guidance from the Sjögren’s Foundation.
We emphasize that this recommendation only applies when the FDA has officially sanctioned the safety of the mRNA vaccinations and the CDC Advisory Committee on Immunization Practices (ACIP) has officially issued its booster dose recommendations. Boosters are expected to become available starting September 20.
Boosters for those who received the J&J COVID-19 vaccination most likely will be recommended, but data analysis has not been completed. The Sjögren’s Foundation will let its members know when a recommendation issued on the J&J vaccination.
Please encourage anyone in your family and community who has not yet received a COVID-19 vaccination to do so as soon as possible for their own protection and for the protection of others.
Click Here for Sjögren's Foundation COVID-19 Vaccination Committee Recommendation on 3rd Dose for Sjögren's Patients Statement
Click Here for Sjögren’s and COVID-19 Vaccination Statement
Click Here for Coronavirus & the Sjögren's Foundation Updates
Sjögren’s COVID-19 Vaccination Committee
Chair:
Alan Baer, MD, Rheumatology and Director of Jerome L. Greene Sjögren’s Syndrome Center, Johns Hopkins, and Chair, Sjögren’s Foundation Medical & Scientific Advisory Council
Committee Members:
Cassandra Calabrese, DO, Rheumatology and Infectious Diseases, Cleveland Clinic
Steven Carsons, MD, Chief of Rheumatology, NYU Winthrop; Senior Associate Dean, Translational Science Integration; and Chair, NYU-Winthrop Vaccine Center for Treatment and Evaluation
Nancy Carteron, MD, Rheumatology and Immunology, University of California San Francisco and Sjögren’s Center, University of California Berkeley
Katherine M. Hammitt, MA, Vice President, Medical & Scientific Affairs, Sjögren's Foundation
Marie Wahren-Herlenius, PhD, Professor of Experimental Rheumatology and Department of Molecular & Cell Biology, Karolinska Institute, Sweden
Click Here to View as a PDF
Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots | CDC Online Newsroom | CDC
The Sjögren’s Foundation COVID Vaccination Committee concurs with the August 18 announcement by U.S. government health officials recommending all Americans, including all Sjögren’s patients, obtain a booster COVID-19 immunization 8 months following the 2nd mRNA COVID-19 vaccination. For those who received a 3rd dose vaccination, new guidance will likely be announced, so watch for news of this guidance from the Sjögren’s Foundation.
We emphasize that this recommendation only applies when the FDA has officially sanctioned the safety of the mRNA vaccinations and the CDC Advisory Committee on Immunization Practices (ACIP) has officially issued its booster dose recommendations. Boosters are expected to become available starting September 20.
Boosters for those who received the J&J COVID-19 vaccination most likely will be recommended, but data analysis has not been completed. The Sjögren’s Foundation will let its members know when a recommendation issued on the J&J vaccination.
Please encourage anyone in your family and community who has not yet received a COVID-19 vaccination to do so as soon as possible for their own protection and for the protection of others.
Click Here for Sjögren's Foundation COVID-19 Vaccination Committee Recommendation on 3rd Dose for Sjögren's Patients Statement
Click Here for Sjögren’s and COVID-19 Vaccination Statement
Click Here for Coronavirus & the Sjögren's Foundation Updates
Sjögren’s COVID-19 Vaccination Committee
Chair:
Alan Baer, MD, Rheumatology and Director of Jerome L. Greene Sjögren’s Syndrome Center, Johns Hopkins, and Chair, Sjögren’s Foundation Medical & Scientific Advisory Council
Committee Members:
Cassandra Calabrese, DO, Rheumatology and Infectious Diseases, Cleveland Clinic
Steven Carsons, MD, Chief of Rheumatology, NYU Winthrop; Senior Associate Dean, Translational Science Integration; and Chair, NYU-Winthrop Vaccine Center for Treatment and Evaluation
Nancy Carteron, MD, Rheumatology and Immunology, University of California San Francisco and Sjögren’s Center, University of California Berkeley
Katherine M. Hammitt, MA, Vice President, Medical & Scientific Affairs, Sjögren's Foundation
Marie Wahren-Herlenius, PhD, Professor of Experimental Rheumatology and Department of Molecular & Cell Biology, Karolinska Institute, Sweden